Innoforce Pharmaceuticals

We are excited to announce that Innoforce has been recognized as the "Best ATMP CDMO in Greater China Region" at the Asia Pacific Biologics CMO Excellence Awards 2024! 🏆 This honor stands as a testament to our unwavering commitment to scientific and technical excellence, innovation, quality, and operational efficiency in the field of advanced therapy medicinal products (ATMP). It reflects the hard work and dedication of our incredible team and the trust of our valued partners. A heartfelt thank you to everyone who contributed to this achievement! We look forward to continuing our journey of excellence and driving the future of ATMP. 🌟 ☞https://lnkd.in/gVseY94a #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy

Min Zhu (SVP, Innoforce) will be speaking at the 3rd Biologics Contract Manufacturing Asia Conference (BCMA) 2024 in Singapore. Her presentation, "CMC Development for mRNA-Based Vaccines and Therapeutics: From Rapid Pandemic Response to Robust Process Development," will offer insights into the latest advancements in RNA therapies. Dr. Min Zhu brings extensive experience from her previous roles at Boehringer Ingelheim and MedImmune/AstraZeneca, where she specialized in process development, and CMC strategy. Join us to explore opportunities for collaboration in RNA therapies. https://lnkd.in/gDaMBtUT #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy

What IF... together, we could overcome the challenges of LNP encapsulation at high mRNA concentrations? High mRNA levels are essential for therapies like protein replacement and gene therapy. At Innoforce, our advanced LNP technology delivers outstanding encapsulation efficiency, even at elevated mRNA concentrations. 💡For example, with mRNA concentrations of 2.5 mg/mL, we achieve over 97% encapsulation efficiency, keeping empty capsids below 6%. Explore how Innoforce can help you meet the challenges across a wide range of mRNA concentrations. ☞https://lnkd.in/gQRhKU-U #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy

What IF... together, we can tackle the challenges in self-amplifying RNA (saRNA) process development and manufacturing? At Innoforce, we're excited to share our expertise in RNA, spanning sizes from 1,000 to 11,000 nt. Our robust platforms for mRNA, circRNA, and saRNA are designed to meet your needs. Due to the special structure and large size of saRNA, it raises extreme challenges to the production and purification processes. Based on the accumulated experience, we have confidently overcome the obstacles, and for saRNA longer than 9,000 nt, we achieve approximately 85% integrity with yields of 7-9 mg/mL. Let’s explore how we can advance your RNA projects together! ☞https://lnkd.in/gfKgSB7G #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy

What IF... together, we can overcome challenges in the process development and manufacturing of circular RNA? At Innoforce, we have extensive experience with various types of RNA. In addition to linear mRNA, our robust platforms also provide solutions for circular RNA, achieving integrity levels around 90%. Discover how our expertise can advance your RNA projects: ☞https://lnkd.in/gfKgSB7G #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy

What IF…together, we can reduce double-stranded RNA (dsRNA) residue for better safety and efficacy? 💡Innoforce’s advanced mRNA processes significantly lower dsRNA compared to traditional methods. Our tailored processes for various indications and applications help control dsRNA residues, enhancing safety and efficacy. 📊For specific RNA molecules, our performance excels with residual dsRNA levels below the limit of quantification (LOQ=0.035 ng/mL), as verified by ELISA. (See attached image) 👉Discover how Innoforce is enhancing mRNA production: https://lnkd.in/gfKgSB7G #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy

What IF... together, we can significantly enhance the efficiency of mRNA in vitro transcription and mRNA integrity control? At Innoforce, we've developed a stable and robust mRNA platform. 💡We offer co-capping and enzymatic capping processes, achieving over 98% capping efficiency for both. 💡Our expertise covers a wide range of RNA sizes (e.g., 1k, 2k, 4k, 7k, 9k, and 12k), ensuring mRNA integrity above 90%, with some achieving greater than 97%! Discover how Innoforce can elevate your mRNA production process. ☞https://lnkd.in/gfKgSB7G #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy

What IF... together, we can significantly reduce lead times and costs for Lentiviral Vectors (LVV) production? With Innoforce, you can expect a 50% cost reduction for large-scale single-batch lots. 💡 Higher LVV yield with higher quality through optimal processes 💡 Raw material cost control 💡 Labor cost control through a well-established training system and operation management Discover how Innoforce can enhance your LVV production process: 👉https://lnkd.in/gNtmQ9X4 #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy

mRNA vaccines saved countless lives globally during the COVID-19 pandemic, and many challenges were discovered and overcome. Although mRNA has proven its effectiveness as an ATMP, mRNA is fragile and can easily degrade. Lipid nanoparticles (LNPs) are crucial as they protect mRNA from degradation and enhance delivery efficiency. Innoforce develops tailored strategies to enhance LNP stability and delivery efficiency, focusing on: ✅ Particle size control ✅ Zeta potential ✅ Encapsulation efficiency ✅ Polydispersity Index (PDI) Download our white paper to learn how Innoforce has improved LNP technology for effective mRNA delivery: ☞https://lnkd.in/gafbPJcp #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy

In large-scale plasmid production, selecting effective downstream purification strategies is vital for ensuring high-quality plasmid products, alongside the importance of the upstream fermentation process. Download our white paper to discover how Innoforce excels in the following areas: 💡Supercoiled plasmid content 💡Plasmid linearization efficiency in mRNA applications 💡Strategies for cost reduction and efficiency improvement 👉https://lnkd.in/gafbPJcp #InnoforcePharma #PlasmidDNA #RNA #LNP #ViralVectors #CellTherapy